Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of OPC-1085EL eye drops in Chinese patients with primary open-angle glaucoma or ocular hypertension
CTR20221401Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Mikeluna in open-angle glaucoma (OAG), ocular hypertension, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Oct 2022; status: completed.
02
Drugs
Mikeluna
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20221401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221401.